GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Forward Dividend Yield %

EV Biologics (EV Biologics) Forward Dividend Yield % : 0.00% (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Forward Dividend Yield %?

As of today (2024-05-21), the Forward Annual Dividend Yield of EV Biologics is 0.00%.

As of today (2024-05-21), the Trailing Annual Dividend Yield of EV Biologics is 0.00%.

YECO's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.555
* Ranked among companies with meaningful Forward Dividend Yield % only.

EV Biologics's Dividends per Share for the three months ended in Dec. 2017 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of EV Biologics's Forward Dividend Yield %

For the Biotechnology subindustry, EV Biologics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where EV Biologics's Forward Dividend Yield % falls into.



EV Biologics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


EV Biologics  (OTCPK:YECO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


EV Biologics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of EV Biologics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021

EV Biologics Announces NFT Dividend

By ACCESSWIRE ACCESSWIRE 07-14-2021

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021